Most Read Articles
Pearl Toh, 08 Jan 2021
Combining the anti-PD-1 antibody sintilimab and a bevacizumab biosimilar significantly improves survival compared with the standard treatment of sorafenib in the first-line setting for patients with advanced, unresectable hepatocellular carcinoma (HCC), according to the ORIENT-32 study presented at ESMO Asia 2020.

Nonaspirin NSAIDs help prevent postcolonoscopy CRC

24 Apr 2020

Use of nonsteroidal anti‐inflammatory drugs (NSAIDs), except aspirin, is associated with a lower risk of colorectal cancer (CRC) after a negative baseline colonoscopy, a recent study reports.

The retrospective study involved a cohort 187,897 patients aged 40 years who underwent colonoscopies (median age at index procedure, 60.6 years; 48.9 percent male). None of the patients had CRC detected within 6 months of index colonoscopy, prior CRC, inflammatory bowel disease and prior colectomy.

There were 21,757 NSAID users (11.6 percent), with a median duration of use of 0.7 years. Fifty-five (0.25 percent) of them developed CRC between 6 and 36 months after index colonoscopy. The resulting 3-year postcolonoscopy (PC)CRC incidence rate was 8.4 per 10,000 person‐years, which was much lower compared with the rate of 16.1 per 10,000 person‐years among NSAID nonusers.

Multivariable Cox proportional analysis confirmed that NSAID use exerted a protective effect on the risk of 3-year PCCRC (adjusted hazard ratio [aHR], 0.54, 95 percent confidence interval [CI], 0.41–0.70) but not on the risk of >3-year PCCRC. The corresponding aHR estimates for proximal and distal cancers were 0.48 (95 percent CI, 0.24–0.95) and 0.55 (95 percent CI, 0.40–0.74).

A duration‐ and frequency-response relationship was seen (ptrend<0.001), such that a longer duration (>1 year; aHR, 0.42, 95 percent CI, 0.26–0.65) and more frequent NSAID use (at least weekly; aHR: 0.46, 95% CI: 0.32‐0.67) conferred greater protection against 3-year PCCRC.

Aspirin, however, provided no risk-reduction benefit (aHR, 1.01, 95 percent CI, 0.80–1.28).

Researchers underscored a need for further investigation to identify the subgroup of patients who will benefit more from NSAIDs, as such drugs are associated with potential adverse effects.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 08 Jan 2021
Combining the anti-PD-1 antibody sintilimab and a bevacizumab biosimilar significantly improves survival compared with the standard treatment of sorafenib in the first-line setting for patients with advanced, unresectable hepatocellular carcinoma (HCC), according to the ORIENT-32 study presented at ESMO Asia 2020.